WILLIAM T. FRIEDEWALD, M.D.; MAX HALPERIN, PH.D.
The efficacy of clofibrate treatment for primary and secondary prevention of ischemic heart disease has been a topic of keen interest for some time, mainly because of the lipid-lowering properties of this drug, and its relatively low incidence of adverse effects. A recent issue of the British Medical Journal contains reports from two completed secondary-prevention trials of clofibrate, one by a group of physicians in the Newcastle-upon-Tyne region (1, 2) and one by a research committee of the Scottish Society of Physicians (2, 3). These trials were separate, cooperative ventures and used a randomized, double-blind design, except for a subsegment
FRIEDEWALD WT, HALPERIN M. Clofibrate in Ischemic Heart Disease. Ann Intern Med. ;76:821–823. doi: 10.7326/0003-4819-76-5-821
Download citation file:
Published: Ann Intern Med. 1972;76(5):821-823.
Cardiology, Coronary Heart Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use